Posted by Michael Wonder on 23 Jan 2026
Enhertu approved in China as the first and only HER2 directed ADC for the second-line treatment of patients with HER2 positive metastatic gastric cancer
22 January 2026 - Based on DESTINY-Gastric04 Phase 3 trial results that showed Enhertu demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to ramucirumab plus paclitaxel.
Enhertu (trastuzumab deruxtecan) has been approved in China for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastro-oesophageal junction adenocarcinoma who have received one prior trastuzumab based regimen. Enhertu previously received conditional approval for third-line or later treatment based on later-line Phase 2 data.
